Free Delivery Over $100
|
|
|||
|
||||
OverviewWhile the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals. Full Product DetailsAuthor: John L. LaMattinaPublisher: John Wiley & Sons Inc Imprint: John Wiley & Sons Inc Dimensions: Width: 15.00cm , Height: 1.50cm , Length: 25.00cm Weight: 2.216kg ISBN: 9781118511329ISBN 10: 1118511328 Pages: 136 Publication Date: 22 January 2013 Audience: Professional and scholarly , Professional & Vocational Format: Digital Publisher's Status: Active Availability: Not yet available  This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release. Table of Contents"Introduction Part 1. ""The 4 Secrets That Drug Companies Don't Want You to Know"" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts"Reviews<p> John LaMattina (ex-head of Pfizer's global R&D) has a new book out about the industry, called Devalued and Distrusted. He tells Pharmalot that he got the idea to write a sequel to his earlier book, Drug Truths, when he appeared on the Dr. Oz show. ( In The Pipeline , 1 December 2012)<p> Summing Up: Recommended. General audiences. ( Choice , 1 September 2013) For those more loosely associated or aspiring to work with in it, I particularly recommend this book as a balanced and informative read on the pressures the industry faces. It should also provide the basis for more reasoned argument and forewarn anyone else potentially ambushed by a TV show. ( ChemMedChem , 19 July 2013) That said, the suggestions made by LaMattina for improvements in productivity and transparency are timely, and the book makes interesting if unexciting reading. ( Chemistry & Industry , 1 June 2013) John LaMattina (ex-head of Pfizer's global R&D) has a new book out about the industry, called Devalued and Distrusted. He tells Pharmalot that he got the idea to write a sequel to his earlier book, Drug Truths, when he appeared on the Dr. Oz show. ( In The Pipeline , 1 December 2012) Author InformationJOHN L. LaMATTINA, PHD, retired as president of Pfizer's Global Research and Development in 2007, where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous honors and awards, including an Honorary Doctor of Science from the University of New Hampshire. Currently a Senior Partner with PureTech Ventures, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D (Wiley). Tab Content 6Author Website:Countries AvailableAll regions |
||||
